Anthropic Establishes Biology Lab
Reuters Reports Quiet Expansion
Anthropic has secretly established a biology lab in the San Francisco Bay Area, as revealed by Reuters (September 18, 2026). The company confirms the existence of the facility but refuses to disclose its intended purpose, ruling out drug discovery.
“We believe that to do biology, the final test is still and will be for a while in real lab work,” Eric Kauderer-Abrams, Anthropic’s head of life sciences, told Reuters.
A Focus on Physical Experiments
The lab serves as a space for running physical biology experiments rather than relying solely on simulations. While the company remains tight-lipped about specific details, it is clear that this move marks a significant expansion into the life sciences domain.
Recent Acquisitions and Growth
This development follows several key acquisitions in the biotech sector over the past year. In April, Anthropic acquired Coefficient Bio for approximately $400 million in stock. Additionally, Vas Narasimhan, CEO of Novartis, joined their board during that same month.
In June, they launched Claude Science, a software tool designed for laboratory research, and have since partnered with Novo Nordisk, Genentech, and Bristol Myers Squibb.
The Lab's Mystery
The lab's specifications remain largely undisclosed. Reuters reports that Anthropic continues to outsource some biological work, indicating that the new facility complements existing partnerships rather than replacing them.
Balancing Simulation and Reality
Anthropic has previously highlighted the risks associated with their advanced models and relaxed safeguards on Claude Fable 5. The establishment of a physical lab adds another layer of complexity to their delicate balance between simulation and real-world applications.